These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22329611)

  • 1. Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
    Ritter JM
    Br J Clin Pharmacol; 2012 Mar; 73(3):331-4. PubMed ID: 22329611
    [No Abstract]   [Full Text] [Related]  

  • 2. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
    Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
    Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone.
    Atar S; Freedberg NA; Antonelli D; Rosenfeld T
    Pacing Clin Electrophysiol; 2003 Mar; 26(3):785-6. PubMed ID: 12698686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Torsade de pointes induced by ajmaline.
    Haverkamp W; Mönnig G; Kirchhof P; Eckardt L; Borggrefe M; Breithardt G
    Z Kardiol; 2001 Aug; 90(8):586-90. PubMed ID: 11565214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced QT prolongation and sudden death.
    Del Rosario ME; Weachter R; Flaker GC
    Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibutilide-induced long QT syndrome and torsade de pointes.
    Gowda RM; Punukollu G; Khan IA; Patlola RR; Tejani FH; Cosme-Thormann BF; Vasavada BC; Sacchi TJ
    Am J Ther; 2002; 9(6):527-9. PubMed ID: 12424513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dofetilide-induced long QT and torsades de pointes.
    Aktas MK; Shah AH; Akiyama T
    Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide.
    Asajima H; Saito N; Ohmura Y; Ohmura K
    Eur J Clin Pharmacol; 2012 Mar; 68(3):331-3. PubMed ID: 21898101
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.
    Letsas KP; Efremidis M; Kounas SP; Pappas LK; Gavrielatos G; Alexanian IP; Dimopoulos NP; Filippatos GS; Sideris A; Kardaras F
    Clin Res Cardiol; 2009 Apr; 98(4):208-12. PubMed ID: 19031039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.
    Wolbrette DL
    Curr Cardiol Rep; 2004 Sep; 6(5):379-84. PubMed ID: 15306095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.
    Bass AS; Hanson LA; Jackson TA
    J Pharmacol Toxicol Methods; 2009; 60(1):51-7. PubMed ID: 19447184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotalol unmasks susceptibility to drug-induced long QT syndrome and torsades de pointes.
    Letsas KP; Efremidis M; Sideris A
    Int J Cardiol; 2008 Mar; 124(3):366-7; author reply 368-9. PubMed ID: 17400314
    [No Abstract]   [Full Text] [Related]  

  • 16. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An explainable algorithm for detecting drug-induced QT-prolongation at risk of torsades de pointes (TdP) regardless of heart rate and T-wave morphology.
    Alahmadi A; Davies A; Royle J; Goodwin L; Cresswell K; Arain Z; Vigo M; Jay C
    Comput Biol Med; 2021 Apr; 131():104281. PubMed ID: 33636421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis.
    Link MS; Foote CB; Sloan SB; Homoud MK; Wang PJ; Estes NA
    Chest; 1997 Aug; 112(2):556-7. PubMed ID: 9266902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
    Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
    Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.